Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry

导出原文传递

翻译打印收藏纠错

作者： Bilton, Diana ^[1] ; Caine, Noreen ^[2] ; Cunningham, Steve ^[3] ; Simmonds, Nicholas J. ^[4] ; Cosgriff, Rebecca ; Carr, Siobhan B.

作者单位： Royal Brompton & Harefield NHS Fdn Trust, Adult Cyst Fibrosis Ctr, London, England ^[1] Royal Brompton & Harefield NHS Fdn Trust, Dept Paediat Resp Med, London, England ^[2] Univ Edinburgh, MRC Ctr Inflammat Res, Edinburgh, Midlothian, Scotland ^[3] UK Cyst Fibrosis Trust, London, England ^[4]

发布时间 2018-08-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The lancet. Respiratory medicine.

2018年6卷7期

495-496页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry

The lancet. Respiratory medicine.

相似文献

The lancet. Respiratory medicine.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Use of a rare disease patient registry in long-term post-authorisation drug studies: a model for collaboration with industry

The lancet. Respiratory medicine.

相似文献

The lancet. Respiratory medicine.

相关期刊

检索历史清除